Abstract

β-amyloid (Aβ) PET is an important tool for quantification of amyloidosis in the brain of suspected Alzheimer disease (AD) patients and transgenic AD mouse models. Despite the excellent correlation of Aβ PET with gold standard immunohistochemical assessments, the relative contributions of fibrillar and nonfibrillar Aβ components to the invivo Aβ PET signal remain unclear. Thus, we obtained 2 murine cerebral amyloidosis models that present with distinct Aβ plaque compositions and performed regression analysis between immunohistochemistry and Aβ PET to determine the biochemical contributions to Aβ PET signal invivo. Methods: We investigated groups of AppNL-G-F and APPPS1 mice at 3, 6, and 12 mo of age by longitudinal 18F-florbetaben Aβ PET and with immunohistochemical analysis of the fibrillar and total Aβ burdens. We then applied group-level intermodality regression models using age- and genotype-matched sets of fibrillar and nonfibrillar Aβ data (predictors) and Aβ PET results (outcome) for both Aβ mouse models. An independent group of double-hit APPPS1 mice with dysfunctional microglia due to knockout of triggering receptor expression on myeloid cells 2 (Trem2-/-) served for validation and evaluation of translational impact. Results: Neither fibrillar nor nonfibrillar Aβ content alone sufficed to explain the Aβ PET findings in either AD model. However, a regression model compiling fibrillar and nonfibrillar Aβ together with the estimate of individual heterogeneity and age at scanning could explain a 93% of variance of the Aβ PET signal (P < 0.001). Fibrillar Aβ burden had a 16-fold higher contribution to the Aβ PET signal than nonfibrillar Aβ. However, given the relatively greater abundance of nonfibrillar Aβ, we estimate that nonfibrillar Aβ produced 79% ± 25% of the net invivo Aβ PET signal in AppNL-G-F mice and 25% ± 12% in APPPS1 mice. Corresponding results in separate groups of APPPS1/Trem2-/- and APPPS1/Trem2+/+ mice validated the calculated regression factors and revealed that the altered fibrillarity due to Trem2 knockout impacts the Aβ PET signal. Conclusion: Taken together, the invivo Aβ PET signal derives from the composite of fibrillar and nonfibrillar Aβ plaque components. Although fibrillar Aβ has inherently higher PET tracer binding, the greater abundance of nonfibrillar Aβ plaque in AD-model mice contributes importantly to the PET signal.

Highlights

  • Positron emission tomography for β-amyloid (Aβ-PET) is widely used for identification and quantification of amyloidosis in the brain of suspected Alzheimer’s disease (AD) patients [1], and has been incorporated into the current research framework for diagnostic recommendations in AD [2]

  • We recently demonstrated that the AppNL-G-F and APPPS1 mouse models exhibit differences in Aβ plaque fibrillarity [14], such that a comparative study of these mice could help to determine the effect of fibrillarity on Aβ-PET signal in vivo

  • Plotting of Aβ-PET results as a linear function of non-fibrillar or fibrillar Aβ at different ages indicated a mismatch between the two mouse models (Fig. 1E)

Read more

Summary

Introduction

Positron emission tomography for β-amyloid (Aβ-PET) is widely used for identification and quantification of amyloidosis in the brain of suspected Alzheimer’s disease (AD) patients [1], and has been incorporated into the current research framework for diagnostic recommendations in AD [2]. Aβ-PET has become a useful tool for the dynamic assessment of neuropathology in transgenic Aβ mouse models [5,6]. Despite the excellent correlation of Aβ-PET with immunohistochemical gold standard assessments of amyloidosis in patients [7,8] and mouse models of AD [6,9], there has remained an uncertainty about the relative contributions of fibrillar and non-fibrillar Aβ components in plaques to the Aβ-PET signal in vivo. This research gap needs to be closed as the two forms have differing neurotoxicity, and there is evidence that alterations in AD-related genes like triggering receptor expressed on myeloid cells 2 (TREM2) and Apolipoprotein E (APOE) alter the net Aβ plaque fibrillarity, which would consecutively bias the relationship between plaque density with Aβ-PET binding in vivo [5]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call